Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
EXEL vs. REGN: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 06'th Mar 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investo
Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments
08:00am, Tuesday, 27'th Feb 2024
Exelixis Inc. (EXEL, Financial) is a pharmaceutical company headquartered in Alameda, California that focuses on developing medicines to treat patients with various types of cancer.
2 Stocks Under $30 to Buy and Hold
08:00am, Monday, 19'th Feb 2024
Exelixis is an innovative, oncology-focused drugmaker with some exciting programs in the works. Adyen's solid position in the fintech industry should allow it to escape from its recent slump.
5 Biotech Stocks to Consider for Your Portfolio in 2024
10:00am, Tuesday, 13'th Feb 2024
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR,
Exelixis (EXEL) Loses -10.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Monday, 12'th Feb 2024
The heavy selling pressure might have exhausted for Exelixis (EXEL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Down -10% in 4 Weeks, Here's Why You Should You Buy the Dip in Exelixis (EXEL)
10:36am, Friday, 09'th Feb 2024
Exelixis (EXEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
3 Medical Stocks to Buy as the Sector Continues to Grow
09:16am, Friday, 09'th Feb 2024
HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.
3 Attractive Medical Stocks to Buy After Earnings
04:56pm, Thursday, 08'th Feb 2024
Following their favorable quarterly results this week here are three intriguing healthcare stocks that investors will want to consider.
EXEL or REGN: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 08'th Feb 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for t
Exelixis (EXEL) Loses -11.72% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 08'th Feb 2024
Exelixis (EXEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss
02:16pm, Wednesday, 07'th Feb 2024
Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
10:13pm, Tuesday, 06'th Feb 2024
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
Exelixis (EXEL) Reports Q4 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 06'th Feb 2024
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Exelixis (EXEL) Tops Q4 Earnings Estimates
06:26pm, Tuesday, 06'th Feb 2024
Exelixis (EXEL) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to loss of $0.03 per share a year ago.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Monday, 29'th Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
